Etienna Bio

Etienna Bio is a biotechnology company specializing in next-generation autologous and cell-enabled biomaterials for regenerative and aesthetic medicine. The company leverages a proprietary platform licensed from UMass Chan Medical School that combines human adipose-derived progenitor cells with a native adipose-derived hydrogel matrix. This biological approach is designed to create durable, naturally integrating tissue for applications such as breast augmentation, reconstructive surgery, and facial fillers. By utilizing a patient's own cells and a biocompatible scaffold, Etienna Bio aims to overcome the limitations of synthetic fillers and traditional implants, prioritizing biological compatibility and scalability. The company is currently advancing its platform through preclinical validation and regulatory engagement.